Certa Therapeutics Announces International Non-Proprietary Name for its First-in-class GPR68 Inhibitor Asengeprast (FT011)
Certa has pioneered drug development targeting GPR68, an important but previously undrugged membrane GPCR receptor, showing it to be a master switch of fibrosis.
- Certa has pioneered drug development targeting GPR68, an important but previously undrugged membrane GPCR receptor, showing it to be a master switch of fibrosis.
- Asengeprast is a novel, first-in-class oral GPR68 antagonist being developed for the treatment of chronic fibrosis in multiple organs.
- Certa Therapeutics is a clinical-stage biotechnology company focused on improving lives by treating patients with debilitating diseases via novel targeted therapies.
- The investigational drug products being developed by Certa Therapeutics are undergoing clinical studies to evaluate the safety and effectiveness in humans.